Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

GlaxoSmithKline is the lead sponsor of 130 current clinical trials in our USA, UK, China, India, Ireland and EU (CTIS) registers. 69 are recruiting patients now. The most common phase is Phase 3. The drugs named most often in its trials are Dostarlimab, Belantamab mafodotin and Dexamethasone. The most-studied condition is Multiple Myeloma.

Company profile on this site (news, sites, medicines, approvals): GSK (GB) →

ClinicalTrials.gov trials by status

Recruiting6959%
Not yet open22%
Active, closed4539%

Trials by phase

Phase 34539%
Phase 22622%
Phase 1/21916%
Phase 11816%
Observational33%
Phase 433%
Phase 2/322%

Clinical trials sponsored by GlaxoSmithKline

116 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH NCT06920043 · Metabolic Dysfunction-Associated Steatohepatitis, Non-alcoholic Fatty Liver Disease	Phase 2	Recruiting	2025-04	USA
A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome NCT06847867 · Myelodysplastic Syndromes Drug: Momelotinib	Phase 2	Recruiting	2025-06	UK, USA
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation NCT07177339 · Pulmonary Disease, Chronic Obstructive Drug: Depemokimab	Phase 3	Recruiting	2025-10	UK, USA, China
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study NCT06979323 · Asthma Drug: Depemokimab	Phase 3	Recruiting	2024-07	UK, USA, China
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301] NCT07099898 · Neoplasms, Lung Drugs: Ris-Rez, Topotecan	Phase 3	Recruiting	2025-08	Ireland, UK, USA
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH NCT07221188 · Non-alcoholic Fatty Liver Disease Drug: Efimosfermin alfa	Phase 3	Recruiting	2025-12	USA
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM) NCT06679101 · Multiple Myeloma, Newly Diagnosed Multiple Myeloma Drugs: Belantamab mafodotin, Daratumumab, Dexamethasone	Phase 3	Recruiting	2024-12	Ireland, UK, USA, India, China
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study NCT04641247 · Ovarian Neoplasms, Breast Neoplasms Drug: Niraparib	Phase 2	Recruiting	2021-04	USA
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma NCT06256588 · ClinicalTrials.gov ↗ · Neoplasms, Head and Neck Drug: Dostarlimab	Phase 3	Recruiting	2024-03	UK, USA, India, China
Safety of Pregnant Subjects Exposed to Ibrexafungerp Including Infant Outcomes NCT05908682 · ClinicalTrials.gov ↗ · Vulvovaginitis, Candidal, Vulvovaginal Candidiasis, Candida Infection	Observational	Recruiting	2025-11	India
A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M) NCT07519395 · Irritable Bowel Syndrome	Phase 2	Recruiting	2026-04	USA
An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) and Primaquine (PQ) When Either Are Taken Together With Chloroquine (CQ) for the Treatment of P. Vivax Malaria in Indian Participants Aged 2 Years and Older NCT06666491 · ClinicalTrials.gov ↗ · Malaria, Vivax Drug: Tafenoquine	Phase 3	Recruiting	2024-11	India
A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a) NCT07645248 · Asthma	Phase 3	Recruiting	2026-09	UK, USA
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM) NCT07227311 · Multiple Myeloma Drugs: Belantamab mafodotin, Bortezomib, Carfilzomib	Phase 2	Recruiting	2026-04	USA
A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline) NCT07585266 · Gastrointestinal Stromal Neoplasms Drug: Imatinib	Phase 3	Recruiting	2026-07	UK, USA, China
Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN NCT06527872 · Lupus Nephritis	Observational	Recruiting	2024-10	USA
A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma NCT07456033 · Asthma Drug: Depemokimab	Phase 3	Recruiting	2026-03	UK, USA
A Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 Inclusive NCT06433921 · ClinicalTrials.gov ↗ · Asthma, Mild Asthma	Phase 1	Recruiting	2024-08	UK
A Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) NCT07782957 · Nasal Polyps Drug: GSK5784283	Phase 3	Recruiting	2026-09	USA
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease NCT05878717 · ClinicalTrials.gov ↗ · Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic Drug: Belimumab	Phase 2/3	Recruiting	2023-09	UK, USA, China
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer NCT05855200 · ClinicalTrials.gov ↗ · Colonic Neoplasms, Neoplasms, Colon Drugs: Capeox, Dostarlimab, Folfox	Phase 3	Recruiting	2023-08	UK, USA, India, China
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments NCT05714839 · ClinicalTrials.gov ↗ · Multiple Myeloma Drugs: Belantamab mafodotin, Dexamethasone, Pomalidomide	Phase 1/2	Recruiting	2023-06	UK, USA, China
A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants NCT06576271 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus Drug: Belimumab	Phase 1	Recruiting	2024-09	UK, USA
A Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants With Uncontrolled Asthma (PERSIST ASTHMA-1) NCT07780643 · Asthma Drug: GSK5784283	Phase 3	Recruiting	2026-08	USA
First Time in Human (FTIH) Study to Investigate the Safety and Preliminary Activity of GSK5533524 Alone or in Combination in Adult Participants With Advanced Solid Tumors NCT07438782 · ClinicalTrials.gov ↗ · Neoplasms	Phase 1	Recruiting	2026-03	UK, USA
A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors NCT07277270 · ClinicalTrials.gov ↗ · Neoplasms Drugs: Bevacizumab, Enzalutamide, Fluorouracil	Phase 1	Recruiting	2025-12	UK, USA
A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1) NCT06431594 · ClinicalTrials.gov ↗ · Solid Tumors, Neoplasms	Phase 1	Recruiting	2024-07	UK, USA
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2) NCT06961214 · ClinicalTrials.gov ↗ · Pulmonary Disease, Chronic Obstructive Drug: Depemokimab	Phase 3	Recruiting	2025-06	UK, USA
A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE) NCT06716606 · ClinicalTrials.gov ↗ · Connective Tissue Diseases Drug: Belimumab	Phase 3	Recruiting	2024-12	UK, USA, China
Open-label Extension Study in Participants With Early Alzheimer's Disease NCT07105709 · ClinicalTrials.gov ↗ · Alzheimer's Disease	Phase 2	Recruiting	2025-08	UK, USA
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial NCT05334368 · ClinicalTrials.gov ↗ · Hypereosinophilic Syndrome Drug: Depemokimab	Phase 3	Recruiting	2022-09	UK, USA, China
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201) NCT06885034 · ClinicalTrials.gov ↗ · Gastrointestinal Neoplasms Drug: Risvutatug Rezetecan	Phase 1/2	Recruiting	2025-06	UK, USA
A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2) NCT06796907 · ClinicalTrials.gov ↗ · Tumours, Gynecological Drugs: Bevacizumab, Dostarlimab	Phase 1/2	Recruiting	2025-03	UK, USA
A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Two GSK3862995B Formulations in Healthy Participants NCT07789899 · ClinicalTrials.gov ↗ · Pulmonary Disease, Chronic Obstructive Drug: GSK3862995B	Phase 1	Recruiting	2026-08	UK
A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis NCT07201051 · ClinicalTrials.gov ↗ · Bronchiectasis Drug: GSK3862995B	Phase 2	Recruiting	2025-10	UK, USA, China
A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease NCT06572384 · ClinicalTrials.gov ↗ · Lung Diseases, Interstitial Drug: Belimumab	Phase 3	Recruiting	2024-09	UK, USA, China
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy NCT07218926 · ClinicalTrials.gov ↗ · Gastrointestinal Neoplasms Drugs: IDRX-42, Sunitinib	Phase 3	Recruiting	2025-12	UK, USA, China
A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103) NCT07602855 · ClinicalTrials.gov ↗ · Neoplasms, Lung Drugs: Ivonescimab, Risvutatug Rezetecan	Phase 1/2	Recruiting	2026-09	USA
A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease NCT06613698 · ClinicalTrials.gov ↗ · Liver Diseases, Alcoholic Drug: GSK4532990	Phase 2	Recruiting	2024-09	UK, USA
A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD) NCT06551142 · ClinicalTrials.gov ↗ · Neoplasms Drugs: Atezolizumab, Bevacizumab, Carboplatin	Phase 1	Recruiting	2024-09	UK, USA
A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH) NCT07704892 · ClinicalTrials.gov ↗ · Metabolic Dysfunction-associated Steatohepatitis Drug: Efimosfermin alfa	Phase 3	Recruiting	2026-07	USA
A Study to Test GlaxoSmithKline's (GSK) Candidate Vaccine-GSK1437173A for Prevention of Shingles in Children With Kidney Transplant NCT04006808 · ClinicalTrials.gov ↗ · Herpes Zoster	Phase 1/2	Recruiting	2019-10	UK
A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer NCT06567782 · ClinicalTrials.gov ↗ · Neoplasms, Colon Drugs: Capeox, Dostarlimab	Phase 2	Recruiting	2025-02	UK
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age NCT06740630 · ClinicalTrials.gov ↗ · Chickenpox Drug: MMR vaccine	Phase 3	Recruiting	2025-01	USA
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1) NCT06959095 · ClinicalTrials.gov ↗ · Pulmonary Disease, Chronic Obstructive Drug: Depemokimab	Phase 3	Recruiting	2025-06	USA, China
A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-2) NCT07780656 · ClinicalTrials.gov ↗ · Pulmonary Disease, Chronic Obstructive Drug: GSK5784283	Phase 3	Recruiting	2026-09	USA
A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH NCT07221227 · ClinicalTrials.gov ↗ · Non-alcoholic Fatty Liver Disease Drug: Efimosfermin alfa	Phase 3	Recruiting	2025-10	USA
A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age NCT06702449 · ClinicalTrials.gov ↗ · Urinary Tract Infections	Phase 1/2	Recruiting	2024-11	USA
A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age NCT07406360 · ClinicalTrials.gov ↗ · Measles, Measles-Mumps-Rubella+Chickenpox Vaccine	Phase 3	Recruiting	2026-05	USA
A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-1) NCT07780669 · ClinicalTrials.gov ↗ · Pulmonary Disease, Chronic Obstructive Drug: GSK5784283	Phase 3	Recruiting	2026-08	USA
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors NCT07213609 · ClinicalTrials.gov ↗ · Neoplasms, Colorectal, Neoplasms	Phase 1/2	Recruiting	2025-10	USA
A Study of Investigational RSV/hMPV Combination and Investigational hMPV Vaccines in Younger and Older Adults NCT07628049 · ClinicalTrials.gov ↗ · Respiratory Syncytial Virus Infections+Metapneumovirus	Phase 1/2	Recruiting	2026-06	USA
A Study on the Efficacy of a Vaccine Against Influenza in Adults ≥65 Years of Age NCT07805707 · ClinicalTrials.gov ↗ · Influenza, Human	Phase 3	Recruiting	2026-09	USA
A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH) NCT07701993 · ClinicalTrials.gov ↗ · Metabolic Dysfunction-associated Steatohepatitis Drug: Efimosfermin alfa	Phase 3	Recruiting	2026-07	USA
First-Time-in-Human Study of GSK5471713 in Adults With mCRPC NCT07332455 · ClinicalTrials.gov ↗ · Neoplasms, Prostate	Phase 1/2	Recruiting	2026-02	USA
A Study of Efimosfermin Alfa in Adults With Hepatic Impairment NCT07358546 · ClinicalTrials.gov ↗ · Non-alcoholic Fatty Liver Disease Drug: Efimosfermin alfa	Phase 1	Recruiting	2026-03	USA
A Comparative Study to Investigate the Difference in Blood Levels of Two Different Formulations of GSK5784283 NCT07712393 · ClinicalTrials.gov ↗ · Asthma Drug: GSK5784283	Phase 1	Recruiting	2026-07	USA
Drug-Interaction Assessment of GSK3772701 in Healthy Male and Female Participants Aged 18 to 55 Years NCT07670377 · ClinicalTrials.gov ↗ · Malaria, Falciparum Drug: Midazolam	Phase 1	Recruiting	2026-06	USA
A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer NCT06990880 · ClinicalTrials.gov ↗ · Neoplasms, Prostate	Phase 1/2	Recruiting	2025-06	USA
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age NCT06855160 · ClinicalTrials.gov ↗ · Chickenpox	Phase 3	Recruiting	2025-04	USA
A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age NCT06693895 · ClinicalTrials.gov ↗ · Chickenpox	Phase 3	Recruiting	2024-11	USA
Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis NCT06517875 · ClinicalTrials.gov ↗ · Primary Myelofibrosis, Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis Drugs: Luspatercept, Momelotinib	Phase 2	Recruiting	2025-02	USA
A Study of Depemokimab in Participants of 6 to 11 Years of Age NCT07671001 · ClinicalTrials.gov ↗ · Asthma Drug: Depemokimab	Phase 3	Recruiting	2026-06	USA
A Study to Investigate the Safety and Efficacy of Efimosfermin Alfa Compared With Placebo in Adult Participants With Alcohol-related Liver Disease (ALD) NCT07791043 · ClinicalTrials.gov ↗ · Liver Diseases, Alcoholic Drug: Efimosfermin alfa	Phase 2	Recruiting	2026-08	USA
A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults NCT07464314 · ClinicalTrials.gov ↗ · Influenza, Human+COVID-19	Phase 1	Recruiting	2026-03	USA
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma NCT05757102 · ClinicalTrials.gov ↗ · Asthma	Phase 3	Recruiting	2023-04	USA
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis NCT07224672 · ClinicalTrials.gov ↗ · Amyloidosis Drugs: Belantamab mafodotin, Bortezomib, Cyclophosphamide	Phase 2	Recruiting	2026-06	USA
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough - China Extension NCT07650084 · ClinicalTrials.gov ↗ · Refractory Chronic Cough Drug: BLU-5937	Phase 3	Recruiting	2025-11	China
A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC) NCT07108270 · ClinicalTrials.gov ↗ · Neoplasms, Endometrial Drugs: Carboplatin, Dostarlimab, Paclitaxel	Phase 2	Recruiting	2025-11	China
A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Given to Healthy Children 4 to 6 Years of Age NCT07742644 · ClinicalTrials.gov ↗ · Measles, Mumps, Rubella	Phase 3	Not yet open	2026-08	USA, China
A Study to Evaluate Safety and Clinical Activity of GSK5926371 in Adult Participants With Relapsed or Refractory B-NHL NCT07607925 · ClinicalTrials.gov ↗ · Lymphoma, Non-Hodgkin	Phase 1/2	Not yet open	2026-06	USA
Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy NCT04655976 · Lung Cancer, Non-Small Cell Drugs: Cobolimab, Docetaxel, Dostarlimab	Phase 2/3	Active, closed	2020-12	UK, USA
A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB) NCT06537414 · Chronic Hepatitis B Virus Infection, Hepatitis B Drug: Bepirovirsen	Phase 2	Active, closed	2024-11	UK, USA, China
A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer NCT05565378 · Lung Cancer, Non-Small Cell Drugs: Belrestotug, Dostarlimab, Nelistotug	Phase 2	Active, closed	2022-10	UK, USA
A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors NCT06077877 · Neoplasms Drug: Niraparib	Phase 1/2	Active, closed	2023-10	USA
Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus) NCT06497504 · Hepatitis B Drug: Bepirovirsen	Phase 2	Active, closed	2024-09	UK, USA
A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC) NCT06472076 · ClinicalTrials.gov ↗ · Lung Cancer, Non-Small Cell Drugs: Belrestotug, Dostarlimab, Pembrolizumab	Phase 3	Active, closed	2024-06	USA, India, China
Phase 2b Study of GSK4532990 in Adults With NASH NCT05583344 · ClinicalTrials.gov ↗ · Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease Drug: GSK4532990	Phase 2	Active, closed	2023-01	UK, USA, India
Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure) NCT04954859 · ClinicalTrials.gov ↗ · Hepatitis B Drug: Bepirovirsen	Phase 2	Active, closed	2021-12	UK, USA, India, China
Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease NCT04915755 · ClinicalTrials.gov ↗ · Neoplasms, Breast Drug: Niraparib	Phase 3	Active, closed	2021-06	Ireland, UK, USA
Safety of Herpes Zoster Subunit (HZ/su) Vaccine During Pregnancy in Adult Women With Immunocompromised Conditions NCT05811754 · Herpes Zoster	Observational	Active, closed	2022-05	USA
Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma NCT04091126 · Multiple Myeloma Drugs: Belantamab mafodotin, Bortezomib, Dexamethasone	Phase 1	Active, closed	2019-12	UK, USA
Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors NCT04446351 · Neoplasms Drugs: Belrestotug, Cobolimab, Dostarlimab	Phase 1	Active, closed	2020-06	USA
A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease NCT06734234 · ClinicalTrials.gov ↗ · Kidney Disease	Phase 1	Active, closed	2024-12	UK, USA
A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults NCT05371080 · ClinicalTrials.gov ↗ · Herpes Zoster	Phase 3	Active, closed	2022-08	UK, USA
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors NCT05277051 · ClinicalTrials.gov ↗ · Neoplasms Drugs: Belrestotug, Dostarlimab, GSK5764227	Phase 1	Active, closed	2022-03	UK, USA, China
Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) NCT05263934 · ClinicalTrials.gov ↗ · Eosinophilic Granulomatosis With Polyangiitis Drugs: Depemokimab, Mepolizumab	Phase 3	Active, closed	2022-07	UK, USA, China
A Study to Evaluate Blood Levels of Bepirovirsen in Adult Participants With Severe or Moderate Kidney Disease NCT07168356 · Hepatitis B Drug: Bepirovirsen	Phase 1	Active, closed	2025-09	USA
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM NCT07084896 · Multiple Myeloma Drugs: Belantamab mafodotin, Nirogacestat	Phase 1/2	Active, closed	2020-06	USA
Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) NCT04162210 · ClinicalTrials.gov ↗ · Multiple Myeloma Drugs: Belantamab mafodotin, Dexamethasone	Phase 3	Active, closed	2020-04	UK, USA, China
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM NCT07217119 · Multiple Myeloma Drugs: Belantamab mafodotin, Feladilimab	Phase 1/2	Active, closed	2019-11	USA
Linerixibat Long-term Safety, and Tolerability Study NCT04167358 · ClinicalTrials.gov ↗ · Cholestasis	Phase 3	Active, closed	2020-07	UK, USA, China
Extended Access of Momelotinib in Adults With Myelofibrosis NCT03441113 · ClinicalTrials.gov ↗ · Neoplasms, Post-polycythemia Vera Myelofibrosis (Post-PV MF), Primary Myelofibrosis (PMF)	Phase 2	Active, closed	2018-05	UK, USA
Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents NCT05087056 · Meningitis, Meningococcal	Phase 2	Active, closed	2021-11	USA
An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study NCT06534892 · ClinicalTrials.gov ↗ · Respiratory Syncytial Virus Infections Drug: RSVPreF3 OA vaccine	Phase 3	Active, closed	2024-08	UK, USA
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma NCT04484623 · ClinicalTrials.gov ↗ · Multiple Myeloma Drugs: Belantamab mafodotin, Bortezomib, Dexamethasone	Phase 3	Active, closed	2020-10	UK, USA, China
A First-time in Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Target Engagement of GSK4528287 in Healthy Participants NCT06681181 · ClinicalTrials.gov ↗ · Colitis, Ulcerative	Phase 1	Active, closed	2024-11	UK
A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer NCT05723562 · ClinicalTrials.gov ↗ · Neoplasms, Rectal Drug: Dostarlimab	Phase 2	Active, closed	2023-04	UK, USA
Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma NCT04246047 · ClinicalTrials.gov ↗ · Multiple Myeloma Drugs: Belantamab mafodotin, Bortezomib, Daratumumab	Phase 3	Active, closed	2020-05	USA, China
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM NCT07217184 · ClinicalTrials.gov ↗ · Multiple Myeloma Drugs: Belantamab mafodotin, Isatuximab	Phase 1/2	Active, closed	2021-07	USA

Showing the 100 most recently updated of 116 trials (recruiting first). The rest are in the country registers linked in each row.

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

GlaxoSmithKline in the EU trials register (CTIS)

14 trials · 2 in Ireland

Authorised or ongoing trials in the EU Clinical Trials Information System with GlaxoSmithKline as sponsor. Some are the same study as a ClinicalTrials.gov record above; the two registries share no common ID. Trials with a site in Ireland are listed first.

Study	Phase	Status	Countries
The MODIFY Study: A Phase 3b/4 randomized, double-blind, placebo-controlled, multicentre study evaluating the impact of early intervention with depemokimab on exacerbation rate, clinical remission, lung function decline, and safety in adults and adolescents with at risk Type 2 asthma, conducted up to 156 weeks. 2025-524463-20-00 · Respiratory Tract Diseases Drugs: Depemokimab, Dopamine	Phase 3	Ongoing	Ireland + 8 more
Phase 3, Multicenter, Randomized, Open-label Clinical Study of GSK5764227, a B7-H3 Antibody Drug Conjugate (ADC), compared with Topotecan in Participants with Relapsed Small Cell Lung Cancer (SCLC) 2025-521627-78-00 · CTIS ↗ · Neoplasms	Phase 3	Ongoing	Ireland + 12 more
A randomized, open-label, multicenter, Phase 3 study to investigate mocertatug rezetecan compared with chemotherapy in participants with endometrial cancer after platinum-based chemotherapy and immunotherapy 2025-523362-25-00 · Neoplasms Drugs: Doxorubicin, Paclitaxel	Phase 3	Authorised	Denmark, Netherlands, Italy + 8 more
A randomized, open-label, multicenter, Phase 3 study to investigate mocertatug rezetecan compared with standard of care in participants with platinum- resistant ovarian cancer. 2025-523361-25-00 · Neoplasms Drugs: Bevacizumab, Doxorubicin, Gemcitabine	Phase 3	Authorised	Denmark, Austria, France + 9 more
A Phase 3, Randomized, Multicenter, Open-Label Study of Velzatinib (GSK6042981) versus Imatinib in Participants with Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) 2025-524934-24-00 · Neoplasms Drug: Imatinib	Phase 3	Ongoing	Italy, Portugal, Germany + 10 more
A Phase 1/2 Open-label, Multi-center Study to Evaluate the Safety and Clinical Activity of GSK5926371 in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas (B-NHL) 2025-524915-36-00 · Neoplasms	Phase 1	Ongoing	Italy, Germany, Spain + 2 more
A Phase 1/2 First-Time-in-Human, open-label, multicenter, dose escalation and dose optimization study of GSK5471713 in adult participants with metastatic castration resistant prostate cancer (mCRPC). 2025-523874-17-00 · Neoplasms	Phase 1	Authorised	Netherlands, France, Spain
A Phase 2, open-label, randomized, dose optimization study evaluating the efficacy and safety of belantamab mafodotin administered in combination with cyclophosphamide, bortezomib, and dexamethasone in adult participants with newly diagnosed amyloid light chain amyloidosis (ALANIS) 2025-522803-60-00 · Immune System Diseases Drugs: Bortezomib, Endoxan	Phase 2	Authorised	Italy, Greece, Spain
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Tolerability of Efimosfermin Alfa in Participants With Known or Suspected F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-2) 2025-523674-16-00 · CTIS ↗ · Nutritional and Metabolic Diseases	Phase 3	Ongoing	Greece, Germany, Belgium + 7 more
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Efficacy of Efimosfermin Alfa in Participants With Biopsy-Confirmed F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-1) 2025-523675-39-00 · CTIS ↗ · Nutritional and Metabolic Diseases	Phase 3	Ongoing	Belgium, Greece, Poland + 7 more
First time in human (FTIH) study to investigate the safety and preliminary activity of GSK5533524 alone or in combination in adult participants with advanced solid tumors 2025-524165-25-00 · CTIS ↗ · Neoplasms	Phase 1	Ongoing	Spain, Denmark, Finland + 1 more
A Phase 1/2 open-label, multicenter study of oral GSK5460025 alone or in combination with other anti-cancer agents in adult participants with Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) solid tumors. 2025-522318-21-00 · CTIS ↗ · Neoplasms	Phase 1	Ongoing	Italy, Denmark, Spain + 3 more
Phase 1, Open-Label, single arm (Non-comparator) Study to Evaluate the Pharmacokinetics and Safety of a Single Dose of Oral Gepotidacin in Addition to Antibacterial Standard of Care in Pediatric Participants from 2 to less than 12 years of age with a Suspected or Confirmed Bacterial Infection or Receiving Prophylaxis with Antibiotics 2025-522916-17-00 · CTIS ↗ · Bacterial Infections and Mycoses	Phase 1	Authorised	Spain, Poland
A study to investigate the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of a CD19/CD20 T-cell engager in participants with B-cell driven ARD. 2025-522932-15-00 · CTIS ↗ · Immune System Diseases	Phase 1	Ongoing	Germany, France, Italy + 2 more

Drugs in GlaxoSmithKline trials

59 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

+ 19 more in the trial list above.

Conditions in GlaxoSmithKline trials

79 conditions

Multiple Myeloma13 Asthma11 Neoplasms9Pulmonary Disease, Chronic Obstructive7Non-alcoholic Fatty Liver Disease5 Hepatitis B4Respiratory Syncytial Virus Infections4Lung Cancer, Non-Small Cell3 Herpes Zoster3 Systemic Lupus Erythematosus3Chickenpox3Neoplasms, Lung2Neoplasms, Head and Neck2Gastrointestinal Neoplasms2Neoplasms, Colon2Liver Diseases, Alcoholic2Neoplasms, Rectal2Metabolic Dysfunction-associated Steatohepatitis2Measles2Neoplasms, Colorectal2Neoplasms, Prostate2Newly Diagnosed Multiple Myeloma1Neoplasms, Breast1Chronic Hepatitis B Virus Infection1

By trial register

Register	Trials	Recruiting
Clinical trials in USA	104	61
Clinical trials in UK	52	31
Clinical trials in China	30	16
Clinical trials in India	8	5
Clinical trials in Ireland	3	2
EU register (CTIS)	14	—

A trial with sites in more than one country appears in each of those registers; recruiting counts cover the trials listed on this page.

Other sponsors in Multiple Myeloma

Sponsor	Trials
Janssen Research & Development	24
AbbVie	13
Pfizer	8
Celgene	5
Zhujiang Hospital	4
Regeneron Pharmaceuticals	3
European Myeloma Network	3
Nanjing IASO Biotechnology	3
Genrix (Shanghai) Biopharmaceutical	3
Xuzhou Medical University	3

Sponsors with the most current trials registered for this condition.

Questions about GlaxoSmithKline trials

How many clinical trials does GlaxoSmithKline sponsor?

GlaxoSmithKline is the lead sponsor of 116 current trials on ClinicalTrials.gov in our USA, UK, China, India and Ireland registers, and 14 authorised or ongoing trials in the EU register (CTIS), as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are GlaxoSmithKline trials recruiting?

Yes. 69 of its 116 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is GlaxoSmithKline testing?

Its current trials name 59 drugs and biologicals as interventions. The most frequent are Dostarlimab (16), Belantamab mafodotin (14), Dexamethasone (11), Depemokimab (9) and Bortezomib (7). The number in brackets is how many of its trials name each drug.

Does GlaxoSmithKline have clinical trials in Ireland?

Yes. 3 trials in our Ireland register (ClinicalTrials.gov), and 2 trials in the EU register (CTIS) with a site in Ireland. Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

GlaxoSmithKline clinical trials